Cipher Pharmaceuticals Inc. (CPHRF) Stock Analysis

Cipher Pharmaceuticals Inc. (CPHRF) Healthcare & Pipeline Overview

Cipher Pharmaceuticals Inc. is a Canadian specialty pharmaceutical company with a focused portfolio of commercial and licensed prescription products, targeting diverse therapeutic areas including dermatology, cardiology, and pain management. The company also maintains a pipeline of development-stage assets, aiming to expand its market presence within the healthcare sector.

What Is the Investment Thesis for CPHRF?

Cipher Pharmaceuticals Inc. presents a profile characterized by its established portfolio of commercial and licensed specialty pharmaceutical products, coupled with an active development pipeline. The company demonstrates strong financial performance with a P/E ratio of 9.00, a significant profit margin of 60.8%, and a gross margin of 74.5%, indicating efficient operations and profitability from its current product sales. Key value drivers include the continued revenue generation from its existing commercial products like Epuris and Ozenoxacin, which address persistent medical needs. Growth catalysts are primarily centered on the successful advancement and potential commercialization of its pipeline assets, such as Trevyent for pulmonary arterial hypertension and CF-101 for severe plaque psoriasis and rheumatoid arthritis. These pipeline candidates represent opportunities to enter new therapeutic markets or expand existing ones. However, the company's small operational footprint with 6 employees and its listing on the OTC market introduce specific considerations regarding scalability and market liquidity.

Based on FMP financials and quantitative analysis

CPHRF Key Highlights

Market capitalization of $267M, reflecting its valuation as a specialty pharmaceutical entity.

• A P/E ratio of 9.00, indicating profitability relative to its share price.
• Impressive profit margin of 60.8%, demonstrating strong net income generation from its revenues.
• Robust gross margin of 74.5%, highlighting efficient cost management in product manufacturing and sales.
• A Beta of -0.16, suggesting low volatility relative to the broader market, though this can be influenced by OTC trading characteristics.

Who Are CPHRF's Competitors?

CPHRF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are CPHRF's Key Strengths?

Diverse portfolio of commercial and licensed specialty pharmaceutical products.

• Strong financial metrics including a 60.8% profit margin and 74.5% gross margin.
• Active pipeline of development-stage products targeting various therapeutic areas.
• Established market presence in Canada for existing products.

What Are CPHRF's Weaknesses?

Small employee base of 6, potentially limiting scalability and internal resources.

• OTC market listing, which can entail lower liquidity and less stringent disclosure requirements.
• Reliance on successful development and commercialization of pipeline products for future growth.
• Beta of -0.16, which while indicating low volatility, might also reflect limited market interest or trading activity.

What Could Drive CPHRF Stock Higher?

Successful regulatory approval and subsequent commercial launch of Trevyent for pulmonary arterial hypertension.

• Positive clinical trial results and progression towards regulatory submission for CF-101 in severe plaque psoriasis or rheumatoid arthritis.
• Advancement of MOB-015 through clinical development stages, demonstrating efficacy for onychomycosis.
• Successful development and market introduction of DTR-001, a non-invasive tattoo removal cream.
• Continued revenue generation and market penetration from established commercial products like Epuris and Ozenoxacin.

What Are the Key Risks for CPHRF?

Clinical trial failures or unexpected adverse events for pipeline candidates, leading to delays or abandonment.

• Intense competition from larger, more resourced pharmaceutical companies in its therapeutic areas.
• Regulatory hurdles and prolonged approval processes for new drugs, impacting time-to-market and costs.
• Dependence on the performance and market acceptance of its existing commercial and licensed product portfolio.
• Challenges associated with its OTC Other listing, including lower liquidity and potential difficulty in raising capital.

What Are the Growth Opportunities for CPHRF?

• The advancement and potential commercialization of Trevyent, a vasodilatory prostacyclin analogue for pulmonary arterial hypertension (PAH), represents a significant growth opportunity. PAH is a serious, progressive disease with a need for effective treatments. Successful clinical development, regulatory approval, and market launch of Trevyent could open access to a specialized and high-value therapeutic market. The timeline for such a complex drug development and approval process is typically multi-year, and specific market size data for Trevyent is not provided in the source.
• CF-101, currently in the pipeline for severe plaque psoriasis and rheumatoid arthritis, offers another substantial growth avenue. Both conditions represent large patient populations with ongoing needs for improved treatment options. Psoriasis and rheumatoid arthritis markets are significant, driven by chronic nature and patient demand for efficacy and safety. Successful development and market entry of CF-101 could position Cipher to address these widespread inflammatory conditions, though specific market size and timelines are not available.
• The development of MOB-015, a topical formulation of terbinafine for onychomycosis (nail fungus), addresses a common dermatological condition. Topical treatments for onychomycosis often face challenges with efficacy and patient compliance. If MOB-015 demonstrates superior efficacy or a more favorable safety profile, it could capture a meaningful share of the dermatological anti-fungal market. Specific market size and development timelines for this product are not detailed in the provided information.
• DTR-001, a tattoo removal cream, targets a growing aesthetic market. As tattoos become more prevalent, so does the demand for removal solutions, which are often invasive and costly. A non-invasive, effective cream could tap into a broad consumer base seeking convenient and less painful alternatives. The aesthetic market, while distinct from traditional pharmaceuticals, offers significant commercial potential. Specific market size and development timelines for DTR-001 are not provided.
• Continued market penetration and potential geographic expansion for existing commercial products like Epuris (severe acne) and Ozenoxacin (impetigo) could drive incremental growth. These products address common dermatological conditions with established patient bases. Optimizing marketing and distribution strategies for these already approved products can lead to sustained revenue generation, leveraging their current market presence in Canada.

What Opportunities Does CPHRF Have?

• Successful regulatory approval and commercial launch of pipeline products like Trevyent, CF-101, MOB-015, and DTR-001.
• Expansion of market share for existing commercial products through enhanced marketing or new indications.
• Potential for new licensing agreements or product acquisitions to diversify the portfolio further.
• Leveraging high profit margins to fund future R&D or strategic initiatives.

What Threats Does CPHRF Face?

• Intense competition from larger pharmaceutical companies and generic manufacturers.
• Regulatory hurdles and potential delays in product approvals.
• Clinical trial failures or unfavorable results for pipeline candidates.
• Patent expirations for existing licensed or commercial products, leading to generic competition.
• Changes in healthcare policies or reimbursement landscapes in Canada.

What Are CPHRF's Competitive Advantages?

• Established portfolio of commercial and licensed specialty pharmaceutical products with existing market approvals in Canada.
• Proprietary formulations and delivery mechanisms for certain products, such as Epuris (CIP-ISOTRETINOIN).
• Strategic licensing agreements that provide access to additional revenue streams and market presence without full development costs.
• Focused expertise in specific therapeutic areas, including dermatology and cardiovascular health.
• An active development pipeline targeting conditions with unmet or underserved medical needs, offering future product differentiation.

What Does CPHRF Do?

Cipher Pharmaceuticals Inc., established in 2000 and headquartered in Oakville, Canada, operates as a specialty pharmaceutical company primarily within the Canadian market. The company's business model revolves around the acquisition, development, and commercialization of a diverse portfolio of prescription products. Its commercial product offerings include Epuris (CIP-ISOTRETINOIN), a specialized formulation for severe acne treatment; Ozenoxacin, used for impetigo in both adult and pediatric patients; Actikerall, indicated for hyperkeratotic actinic keratosis; Vaniqa, a prescription cream for reducing unwanted facial hair in women; BRINAVESS, a treatment for sinus rhythm in adults; and AGGRASTAT, an intravenous anti-platelet drug. These products address a range of medical needs, from dermatology to cardiovascular health. In addition to its directly commercialized products, Cipher Pharmaceuticals Inc. also manages a portfolio of licensed products. These include CIP-Isotretinoin; Lipofen (CIP-Fenofibrate), a formulation for hyperlipidemia, a cholesterol disorder; and Conzip/Durela (CIP-Tramadol), an extended-release formulation for moderate to moderately severe pain management. This dual approach of commercialization and licensing allows the company to leverage existing market approvals and distribution channels. Looking to future growth, Cipher Pharmaceuticals Inc. maintains an active pipeline of development-stage products. Notable candidates include Trevyent, a vasodilatory prostacyclin analogue aimed at treating pulmonary arterial hypertension; CF-101, under investigation for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical terbinafine formulation for onychomycosis; and DTR-001, a tattoo removal cream. With a compact team of 6 employees, the company focuses on strategic product management and pipeline advancement within the highly regulated pharmaceutical landscape of Canada.

What Products and Services Does CPHRF Offer?

• Develop and commercialize specialty pharmaceutical products in Canada.
• Offer Epuris (CIP-ISOTRETINOIN) for severe acne treatment.
• Provide Ozenoxacin for impetigo in adults and pediatric patients.
• Market Actikerall for hyperkeratotic actinic keratosis.
• Distribute Vaniqa, a prescription cream for unwanted facial hair in women.
• Supply BRINAVESS for the treatment of sinus rhythm in adults.
• Offer AGGRASTAT, an intravenous anti-platelet drug.
• Manage licensed products including CIP-Isotretinoin, Lipofen (CIP-Fenofibrate) for hyperlipidemia, and Conzip/Durela (CIP-Tramadol) for pain.
• Advance a pipeline of development-stage products like Trevyent for pulmonary arterial hypertension and CF-101 for psoriasis/rheumatoid arthritis.

How Does CPHRF Make Money?

• Generates revenue from direct sales of commercialized prescription pharmaceutical products in Canada.
• Earns income from licensing agreements for various pharmaceutical formulations, including CIP-Isotretinoin and Lipofen.
• Invests in research and development for pipeline products, aiming for future commercialization and market expansion.
• Focuses on specialty therapeutic areas, often addressing specific medical needs with differentiated formulations.
• Leverages a lean operational structure with a small employee base to manage its product portfolio.

What Industry Does CPHRF Operate In?

Cipher Pharmaceuticals Inc. operates within the Drug Manufacturers - Specialty & Generic industry, a segment of the broader Healthcare sector in Canada. This industry is characterized by a focus on developing and commercializing specialized pharmaceutical products, often targeting niche markets or offering improved formulations of existing drugs. The competitive landscape includes both larger multinational pharmaceutical companies and smaller, agile specialty firms. Market trends often involve increasing demand for innovative treatments, particularly in areas like dermatology and chronic disease management, alongside pressures for cost-effective generic alternatives. Cipher's position is defined by its portfolio of commercialized and licensed products, such as Epuris for acne and Lipofen for hyperlipidemia, which allows it to serve established patient populations. Its pipeline, including candidates for pulmonary arterial hypertension and psoriasis, indicates an intent to capture new market share in areas with unmet medical needs, navigating a highly regulated environment.

Who Are CPHRF's Key Customers?

• Patients suffering from severe acne, impetigo, hyperkeratotic actinic keratosis, and unwanted facial hair.
• Healthcare professionals, including dermatologists, cardiologists, and general practitioners, who prescribe their products.
• Hospitals and clinics that utilize drugs like BRINAVESS and AGGRASTAT.
• Patients requiring treatment for hyperlipidemia and moderate to moderately severe pain.
• Individuals seeking solutions for pulmonary arterial hypertension, severe plaque psoriasis, rheumatoid arthritis, onychomycosis, and tattoo removal in the future.

Cipher Pharmaceuticals Inc. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 29.3% above estimates on average.

Quarterly Financial Performance: Cipher Pharmaceuticals Inc.

Revenue for Cipher Pharmaceuticals Inc. came in at $11.8M during Q2 FY2026, a 4.6% contraction versus the preceding quarter. The company recorded net income of $3.9M, with diluted EPS of $0.15. Revenue has contracted over three consecutive quarters, which investors in this micro-cap Healthcare stock should monitor closely. Across the four most recent quarters, CPHRF averaged $0.28 in diluted EPS.

CPHRF Valuation & Market Position

With a $267M market cap, Cipher Pharmaceuticals Inc. sits in the micro-cap segment of the market.

Return on equity for Cipher Pharmaceuticals Inc. stands at 25.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 7.9%, showing how much profit it generates from its asset base. A current ratio of 1.25 indicates the company holds enough short-term assets to cover its near-term obligations.

Cipher Pharmaceuticals Inc.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 9.91 places it in the safe zone, indicating low near-term bankruptcy risk.

Company Profile

Cipher Pharmaceuticals Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Mississauga, CA. The company is led by CEO Craig J. Mull. CPHRF has traded publicly since 2006.

CPHRF Financials

CPHRF Latest News

CPHRF Analyst Consensus

CPHRF MoonshotScore

What Investors Ask About Cipher Pharmaceuticals Inc. (CPHRF) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources